Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection. by Singh, Ravesh. et al.
JOURNAL OF VIROLOGY, Jan. 2011, p. 208–216 Vol. 85, No. 1
0022-538X/11/$12.00 doi:10.1128/JVI.01810-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Association of TRIM22 with the Type 1 Interferon Response
and Viral Control during Primary HIV-1 Infection
Ravesh Singh,1 Gaurav Gaiha,2 Lise Werner,3 Kevin McKim,2 Koleka Mlisana,3 Jeremy Luban,4
Bruce D. Walker,1,2,5 Salim S. Abdool Karim,3 Abraham L. Brass,2 Thumbi Ndung’u,1,2,3*
and the CAPRISA Acute Infection Study Team
HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of
KwaZulu-Natal, Durban, South Africa1; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of
Technology and Harvard University, Boston, Massachusetts2; Centre for the AIDS Programme of
Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa3;
Department of Microbiology, University of Geneva, Geneva, Switzerland4; and
Howard Hughes Medical Institute, Chevy Chase, Maryland5
Received 26 August 2010/Accepted 14 October 2010
Type 1 interferons (IFNs) induce the expression of the tripartite interaction motif (TRIM) family of E3
ligases, but the contribution of these antiviral factors to HIV pathogenesis is not completely understood. We
hypothesized that the increased expression of select type 1 IFN and TRIM isoforms is associated with a
significantly lower likelihood of HIV-1 acquisition and viral control during primary HIV-1 infection. We
measured IFN-, IFN-, myxovirus resistance protein A (MxA), human TRIM5 (huTRIM5), and TRIM22
mRNA levels in peripheral blood mononuclear cells (PBMCs) of high-risk, HIV-1-uninfected participants and
HIV-1-positive study participants. Samples were available for 32 uninfected subjects and 28 infected persons,
all within 1 year of infection. HIV-1-positive participants had higher levels of IFN- (P  0.0005), MxA (P 
0.007), and TRIM22 (P  0.01) and lower levels of huTRIM5 (P < 0.001) than did HIV-1-negative partici-
pants. TRIM22 but not huTRIM5 correlated positively with type 1 IFN (IFN-, IFN-, and MxA) (all P <
0.0001). In a multivariate model, increased MxA expression showed a significant positive association with viral
load (P  0.0418). Furthermore, TRIM22 but not huTRIM5, IFN-, IFN-, or MxA showed a negative
correlation with plasma viral load (P  0.0307) and a positive correlation with CD4 T-cell counts (P 
0.0281). In vitro studies revealed that HIV infection induced TRIM22 expression in PBMCs obtained from
HIV-negative donors. Stable TRIM22 knockdown resulted in increased HIV-1 particle release and replication
in Jurkat reporter cells. Collectively, these data suggest concordance between type 1 IFN and TRIM22 but not
huTRIM5 expression in PBMCs and that TRIM22 likely acts as an antiviral effector in vivo.
Tripartite interaction motif (TRIM) E3 ligases represent a
recently described family of proteins with potent antiviral ac-
tivity (39). There are approximately 70 TRIM family members,
and they are characterized by the presence of a tripartite motif,
which consists of a RING domain, one or two B-box motifs,
and a coiled-coil region (21, 29, 39). The presence of the RING
domain suggests that these proteins function as E3 ubiquitin
ligases and mediate ubiquitylation events (6). The E3 ubiquitin
ligase activity of the RING domain is important for the anti-
retroviral function of many TRIM proteins (29, 38).
The prototype member of this family, TRIM5, is respon-
sible for the complete block of HIV-1 replication in Old World
monkey cells (33, 36). This effect is mediated through the
interaction of rhesus monkey TRIM5 (TRIM5rh) with the
HIV-1 capsid (36). Further studies suggested that in addition
to the effects of TRIM5rh on HIV via binding to capsid, other
mechanisms of viral inhibition are possible (27, 31). TRIM5
is responsible for the species-specific postentry restriction of
retroviruses, such as N-tropic murine leukemia virus (N-
MuLV) and HIV-1, in primate cells (36, 45). Other TRIM E3
ligases with antiviral activity have been described (45). TRIM
family proteins affect specific steps in the HIV life cycle (13).
TRIM proteins appear to mediate their antiviral activities via
diverse mechanisms: interference with the uncoating of the
viral preintegration complex was noted for TRIM5 (24), and
an inhibition of viral budding has been described for TRIM22
(26).
Although the antiretroviral activity of TRIM E3 ligases is
established, the contribution of this family of proteins to pro-
tection against HIV-1 infection or to the control of disease
progression is largely unknown. Many in vitro studies have
suggested that human TRIM5 (huTRIM5) has little effect
on HIV replication. However, some huTRIM5 genetic vari-
ants have been associated with reduced susceptibility to HIV
infection (14, 35), suggesting that huTRIM5 may have a pro-
tective role in infection. Modest effects of huTRIM5 genetic
polymorphisms on the rate of disease progression have also
been reported (9, 41), and it was suggested previously that
human TRIM5 may select for HIV-1 escape mutants after a
prolonged duration of infection (17).
In a prospective cohort study of HIV-1-negative individuals
at high risk for HIV-1 infection, we have recently shown that
elevated levels of expression of huTRIM5 are associated with
decreased susceptibility to HIV-1 infection (34). Furthermore,
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we found that huTRIM5 mRNA levels were neither actively
downregulated nor upregulated among individuals in this co-
hort who eventually became HIV-1 infected. The latter finding
was surprising, because previous studies demonstrated that
type 1 interferons (IFNs) are dysregulated during HIV-1 in-
fection (10, 15), and TRIM5 is a well-known type 1 IFN-
inducible gene (1, 31). Therefore, we would have expected to
observe trends for huTRIM5 similar to those reported for
type 1 IFN. In addition to TRIM5, several TRIM proteins
with antiviral activity were recently described and were shown
to be IFN inducible (2, 39). However, there are also notable
exceptions to this IFN inducibility rule (4, 28). IFNs are them-
selves the main mediators of innate immunity to viral infection,
and they play a significant role by upregulating the expression
of many antiviral effectors within the cell (5, 30). Our under-
standing of the type 1 IFN regulation of TRIMs is complicated
by the fact that IFN- has 13 functional isoforms. It is unclear
whether all these isoforms have the same effect on IFN-stim-
ulated genes (23).
Here we investigated the expression of the type 1 IFNs
IFN- (IFN-2b isoform), IFN-, a surrogate interferon-in-
ducible gene (myxovirus resistance protein A [MxA]), and
TRIM22 in a longitudinal cohort of black African females at
high risk for HIV-1 infection, for which we have previously
demonstrated that enhanced TRIM5 mRNA expression is
associated with reduced susceptibility to HIV infection (34).
TRIM22 was selected for this analysis because in addition to
TRIM5, it is one of the relatively well-characterized TRIM
E3 ligases, has been shown to be type 1 IFN inducible in vitro,
and appears to possess anti-HIV-1 activity (2, 4, 25). Specifi-
cally, we tested the hypotheses that the increased expression of
type 1 IFNs and TRIM22 is associated with a significantly
lower likelihood of HIV-1 acquisition and lower viral loads or
higher CD4 T-cell counts during primary HIV-1 infection.
We tested whether there are differences in mRNA levels of select
type 1 IFNs, huTRIM5, and TRIM22 in peripheral blood mono-
nuclear cells (PBMCs) from HIV-negative versus HIV-positive
individuals. We used multivariate analysis models in order to
better understand the kinetics and antiviral implications of the
expression of these genes in vivo. Finally, we performed in vitro
experiments to better understand the relationship between type 1
IFNs, TRIM22 expression, and antiviral activity.
MATERIALS AND METHODS
Subjects. Study subjects were part of the CAPRISA 002 Acute Infection
Study, which is an observational natural history study of HIV-1 subtype C
infection established in Durban, South Africa, in 2004 (34, 40). The cohort
consisted of 245 high-risk seronegative women who were monitored to identify
acute or recent infections. Participants were enrolled into the acute-infection
phase if they were antibody positive within 5 months of a previous antibody-
negative test or if they had evidence of viral replication without HIV-1 antibod-
ies, as assessed by rapid tests and PCR testing. Women from other seroincident
cohorts in Durban were enrolled into CAPRISA 002 if they met the above-
described criteria. Time of infection was defined as the midpoint between the last
HIV antibody-negative test and the first HIV antibody-positive test or 14 days
prior to the first positive HIV RNA PCR assay for those identified as being
antibody negative but HIV RNA PCR positive. The study was approved by the
Biomedical Research Ethics Committee of the University of KwaZulu-Natal,
and participants provided written informed consent.
PBMCs from a total of 32 HIV-1-uninfected and 28 recently HIV-1-infected
individuals from the CAPRISA study cohort were available for use in this study.
Sample processing, viral load quantification, and CD4 cell enumeration.
PBMCs were isolated by Ficoll-Histopaque (Sigma) density gradient centrifuga-
tion from blood within 6 h of phlebotomy and frozen in liquid nitrogen until use.
Viral load was determined by using the automated COBAS Amplicor HIV-1
Monitor Test v1.5 (Roche). CD4 cells were enumerated by using the Multitest
kit (CD4/CD3/CD8/CD45) on a four-parameter FACSCalibur flow cytometer
(Becton Dickinson).
Lentivirus production. Lentiviruses containing short hairpin RNAs (shRNAs)
expressed under the control of the U6 promoter in a lentiviral vector (pLKO.1)
that also confers puromycin resistance were generated in 293T cells as previously
described (22).
Plasmids pLKO.1, pLKO.1/scrambleshRNA (Harvard Institute of Proteomics),
and pLKO.1/TRIM22shRNA 3UTR (5-CCGGTATTGGTGTTCAAGACTAT
ATCTCGAGATATAGTCTTGAACACCAATATTTTTG-3; Sigma Aldrich)
were used. 293T cells were transfected with a packaging plasmid (pCMVdR8.2
dvpr; Addgene), a pRSV-Rev (Addgene) envelope plasmid (VSV-G/pMD2.G;
Addgene), and the corresponding pLKO.1 vector.
Viral infection. Peripheral blood mononuclear cells (1  106 cells) isolated
from healthy HIV-negative donors were placed into a 12-well plate in the pres-
ence or absence of CD3.8 antibody (0.5 g/ml) and incubated for 3 days at 37°C
in 5% CO2. Following stimulation, cells were washed with R10 medium and then
infected with HIV-IIIB (NIH AIDS Reagent Repository) by spinoculation (2 h
at 2,500 rpm at 37°C) at 2  105 cells/well in a 96-well plate. Virus was subse-
quently removed, and cells were washed once and then allowed to incubate for
an additional 3 days before analysis of TRIM22 expression by Western blotting.
For Jurkat LTR-G cell experiments (JLTR-G; NIH AIDS Reagent Reposi-
tory), cells were transduced by using spinoculation as described above, and the
cells were puromycin selected 48 h later. Stably transduced JLTR-G cells in
96-well plates (2  105 cells/well) were incubated with IFN-2a (1,000 U/ml;
Pestka Biomedical Laboratories, NJ) for 24 h. Cells were then infected by
spinoculation with HIV-IIIB. Cells were allowed to incubate for 2 h and then
analyzed for HIV long terminal repeat (LTR)-dependent green fluorescent pro-
tein (GFP) expression by flow cytometry on days 2 and 7. Cell culture superna-
tants from day 7 samples were harvested and analyzed by a p24 enzyme-linked
immunosorbent assay (ELISA) (Becton Dickinson).
Type 1 IFN stimulation of immune cell lines. CEM, Jurkat, and THP1 cells in
96-well plates (2  105 cells/well) were stimulated with IFN- for 6 h, whereupon
gene expression was assessed for TRIM5 and TRIM22.
RNA isolation and analysis. For all samples, RNA was extracted immediately
after thawing and counting of PBMCs without in vitro stimulation. RNA was
extracted from 2  106 PBMCs by using TRIzol LS reagent (Invitrogen). The
total RNA concentration was quantified, and samples were used only if the
optical density at 260 nm (OD260)/OD280 ratio was 1.90 or greater. All RNA
samples were DNase treated. One microgram of total RNA from each sample
was reversed transcribed by using the iScript cDNA synthesis kit (Bio-Rad).
RNA quantitation by real-time PCR. The PCR primers and cycling conditions
used for IFN-, IFN-, MxA, huTRIM5, and TRIM22 real-time quantitative
PCR are provided in Table 1. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was determined to be the most suitable reference gene based on PCR
efficiency. Each PCR mixture consisted of 3 mmol/l MgCl2, the respective
primers (0.5 pmol/l for MxA, huTRIM5, and TRIM22 and 0.25 pmol/l for
IFN-, IFN-, and GAPDH), 1 l Fast Start SYBR green I (Roche), 1 g
cDNA, and water (10-l total volume). Reactions were run with a Roche Light-
Cycler v1.5 instrument (1 cycle at 95°C for 10 min and then 45 cycles of dena-
turation, annealing, and extension [Table 1]). To confirm amplification specific-
ity, the PCR products were subjected to a melting-curve analysis and agarose gel
electrophoresis. Serial dilutions of cDNA from total RNA were performed for
each target gene. These served as standard curves for quantitative analysis.
Western blotting. Antibodies used in this study were rabbit polyclonal anti-
TRIM22 (Prestige, catalog number HPA003575; Sigma), mouse monoclonal
anti-Ran (catalog number R4777; Sigma), or rabbit polyclonal anti-IFITM1
(catalog number ab70477; Abcam). Antibody-antigen complexes were detected
by using enhanced chemiluminescence reagents (Invitrogen).
Statistical analysis. The generation of dot plots, nonparametric statistical
analysis, and correlations (Pearson) were performed by using the statistical
programs Instat Graphpad Prism V.5. and SAS. Values are expressed as medi-
ans. Differences between groups were evaluated by using a Student’s t test. We
correlated huTRIM5 and TRIM22 to type 1 IFN (MxA, IFN-, and IFN-)
gene expression values and to each other. Pearson correlations were performed
on log-transformed data. Univariate and multivariate generalized estimating
equation (GEE) models were fitted to huTRIM5, TRIM22, MxA, IFN-, and
IFN- expressions; viral loads; and CD4 cell counts. Viral loads and expression
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levels were log transformed, while square root transformation was applied to
CD4 count data to ensure normality.
RESULTS
Relative expression levels of type 1 IFN (IFN- and IFN-),
MxA, and huTRIM5 in PBMCs from HIV-1-uninfected ver-
sus HIV-1-infected subjects. We have previously shown that
HIV-negative patients have higher levels of huTRIM5 than
do HIV-1-positive patients (34). However, in matched pre- and
postinfection samples, we did not see a significant dysregula-
tion of TRIM5. This result was surprising, as TRIM5 is a
type 1 IFN-responsive gene, and type 1 IFN is dysregulated in
primary HIV-1 infection (15). Furthermore, we found that
women at high risk for HIV-1 infection who did not serocon-
vert following 2 years of follow-up had significantly higher
TRIM5 mRNA levels in PBMCs than did seroconverters
(34). A possible explanation for the latter finding is that high-
risk nonseroconverter study participants have generally higher
levels of innate antiviral defense mechanisms, perhaps medi-
ated through type 1 IFN, thus providing an explanation for our
observation of elevated huTRIM5 levels among nonserocon-
verters. We therefore sought to better understand the relation-
ship between TRIM5, IFN-, IFN-, and a type 1 IFN-in-
ducible gene, MxA.
We compared mRNA levels of IFN-, IFN-, MxA, and
TRIM5 in PBMCs from HIV-1-negative versus HIV-1-infected
samples collected within the first 12 months postinfection.
There were 32 individual HIV-1-negative samples available
and 28 HIV-1-infected samples. Samples from HIV-1-positive
individuals were available at multiple time points postinfec-
tion, and samples closest to the 12-month-postinfection time
point were included in the analyses presented here. Only pa-
tients that remained HIV-1 negative upon 2 years of follow-up
were used for this analysis (n  19). The expression values
were log transformed to ensure normality. Median expression
levels between HIV-negative and HIV-positive samples were
compared by using an unpaired Student’s t test. There were no
significant differences in IFN- expression between HIV-1-
negative and –positive participants (Fig. 1A). HIV-1-positive
participants had significantly higher levels of IFN- (P 
0.0005) and MxA (P  0.007) (Fig. 1B and D). As we have
previously reported, HIV-1-negative PBMCs had significantly
higher levels of TRIM5 than did HIV-1-positive PBMCs (P 
0.0001) (Fig. 1C).
We next investigated the relationship between TRIM5 and
type 1 IFN expression in HIV-1-negative and -positive sam-
ples. There was no correlation between TRIM5 and IFN- or
MxA (Fig. 1E and G) for both negative and positive time
points. All HIV-1-negative (n  32) and HIV-1-positive (n 
75) samples available at multiple time points were used for this
analysis. We found a significant inverse correlation between
IFN- and TRIM5 in both HIV-1-negative (r  	0.49; P 
0.004) and HIV-positive (r  	0.39; P  0.0008) samples (Fig.
1F). As expected, our data also indicated that MxA is a suitable
surrogate for type 1 IFN induction, because MxA mRNA lev-
els showed a significant positive correlation with IFN- in both
HIV-1-negative (r  0.8; P  0.0001) and HIV-1-positive (r 
0.81; P  0.0001) PBMCs. MxA mRNA levels were also sig-
nificantly correlated with IFN- levels in both HIV-1-negative
(r  0.7; P  0.0001) and HIV-1-positive (r  0.8; P  0.0001)
samples (Fig. 1H). Thus, in this cohort of individuals at high
risk for HIV-1 infection in a high-prevalence setting, the level
of TRIM5 was higher in HIV-1-negative than in HIV-1-pos-
itive PBMCs, and surprisingly, there was an inverse correlation
between TRIM5 and IFN-.
Expression of TRIM22 in PBMCs from HIV-1-uninfected
versus -infected subjects and association between type 1 IFN
and TRIM22. We next wished to evaluate the expression of the
TRIM22 gene, which is located downstream of TRIM5 on
chromosome 11 (location 11p15) (32), because it was shown
previously to be type 1 IFN inducible in vitro and has known
antiviral activity (2). HIV-1-positive participants had higher
mRNA levels of TRIM22 than did HIV-negative patients (P 
0.01) (Fig. 2A). IFN- mRNA levels positively correlated with
TRIM22 expression levels in both HIV-negative (r  0.91; P 
0.0001) and HIV-1-positive (r  0.9; P  0.0001) subjects (Fig.
TABLE 1. Primers used in this study
Gene GenBankaccession no. Sequence (5–3)
a Cycling conditions (denaturation, annealing,
and extension)
MxA NM_0024462 5-AAGCTGATCCGCCTCCACTT-3 (F) 95°C for 6 s, 60°C for 6 s, and 72°C for 10 s
5-TGCAATGCACCCCTGTATACC-3 (R)
IFN- NM_000069 5-GAAACCACTGACTGTATATTGTGTGAAA-3 (F) 95°C for 6 s, 60°C for 6 s, and 72°C for 10 s
5-CAGCGTCACTAAAAACACTGCTTT-3 (R)
IFN- L41942 5-AGTCAGAGGGAATTGTTAAGAAGCA-3 (F) 95°C for 6 s, 60°C for 6 s, and 72°C for 10 s
5-TTTGGAATTAACTTGTCAATGATATAGGTG-3 (R)
huTRIM5 NM_033034 5-AGGAGTTAAATGTAGTGCT-3 (F) 95°C for 6 s, 60°C for 15 s, and 72°C for 6 s
5-ATAGATGAGAAATCCATGGT-3 (R)
TRIM22 NM_006074 5-GGTTGAGGGGATCGTCAGTA-3 (F) 95°C for 6 s, 60°C for 6 s, and 72°C for 10 s
5-TTGGAAACAGATTTTGGCTTC-3 (R)
GAPDH NM_002046 5-AAGGTCGGAGTCAACGGATT-3 (F) 95°C for 6 s, 65°C for 6 s, and 72°C for 6 s
5-CTCCTGGAAGATGGTGATGG-3 (R)
a F, forward; R, reverse.
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2B). IFN- also showed a significant positive correlation with
TRIM22 in both HIV-negative (r  0.93; P  0.0001) and
HIV-1-positive (r  0.87; P  0.0001) subjects (Fig. 2C). Like-
wise, MxA mRNA levels correlated positively with TRIM22
mRNA levels in both HIV-1-negative (r  0.81; P  0.0001)
and HIV-1-positive (r  0.92; P  0.0001) subjects (Fig. 2D).
Thus, TRIM22 positively correlates with type 1 IFN expression
in both HIV-1-negative and HIV-1-positive PBMCs in vivo.
Expression of type 1 IFN (IFN- and IFN-), MxA, and
TRIM22 mRNA in PBMCs at baseline (study enrollment)
from nonseroconverters versus seroconverters. We next ad-
dressed whether preinfection samples from seroconverters dif-
fered from those from nonseroconverters in IFN-, IFN-,
MxA, and TRIM22 expression levels. Although seroconverters
showed generally higher mRNA levels of IFN- and MxA than
nonseroconverters, the differences between the groups did not
FIG. 1. Expression of type 1 IFN (IFN-, IFN-, and MxA) and huTRIM5 in PBMCs from HIV-1-uninfected versus HIV-1-infected subjects
and association between type 1 IFN and huTRIM5. The samples from infected participants were all collected within 12 months of infection. At
least two time points were available postinfection for the primary infection samples. For the HIV-1-positive group we compared one time point,
closest to the set point of 12 months postinfection (n  28). Only patients that remained HIV-1 negative upon follow-up were used for this analysis
(n  19). Data are depicted as the normalized ratio of huTRIM5, IFN-, or IFN- versus GAPDH. The expression values were log transformed
to ensure normality. Median expression levels between HIV-negative and HIV-positive samples were compared. The differences between groups
were evaluated by using an unpaired Student’s t test. A P value of 0.05 was considered statistically significant. Pearson correlations were
performed for huTRIM5 and IFN-, IFN-, or MxA for both negative and positive patients. Pearson correlations were also performed for MxA
and IFN- or IFN- for both negative and positive patients.
FIG. 2. Expression of TRIM22 in PBMCs from HIV-1-uninfected versus HIV-1-infected subjects and association between type 1 IFN and
TRIM22. The samples from infected participants were all collected within 12 months of infection (primary infection phase). At least two time
points were available postinfection for the primary infection samples. For the HIV-1-positive group we compared one time point, closest to the
set point of 12 months postinfection (n  28). Only patients that remained HIV-1 negative upon follow-up were used for this analysis (n  19).
Data are depicted as the normalized ratio of TRIM22 versus GAPDH. The expression values were log transformed to ensure normality. Median
expression levels between HIV-negative and HIV-positive samples were compared. The differences between groups were evaluated by using an
unpaired Student’s t test. A P value of 0.05 was considered statistically significant. Pearson correlations were performed for TRIM22 and IFN-,
IFN-, or MxA for both negative and positive patients.
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reach statistical significance (Fig. 3A and C). Individuals who
became HIV-1 positive (n  13) during the 2-year study fol-
low-up period had significantly higher IFN- (P  0.0001) and
TRIM22 (P  0.0022) mRNA levels preinfection than did
those who remained HIV-1 negative (n  19) (P  0.0001; P 
0.0022) (Fig. 3B and D).
Association between antiviral gene expression, viral load,
and CD4 T-cell counts. To determine if IFN-, IFN-, MxA,
huTRIM5, and TRIM22 gene expressions had functional im-
plications for viral control during primary infection, we used a
generalized estimating equation (GEE) model to evaluate viral
load or CD4 T-cell counts, adjusting for repeated measure-
ments for the same individual. In the univariate models, MxA
displayed a statistically significant association with HIV-1
plasma viral load. For every log increase in MxA mRNA levels,
the viral load increased by 0.29 log copies/ml (P  0.0444).
IFN- also showed a positive association with viral load; how-
ever, this was not statistically significant (P  0.0995).
Following adjustment for the other antiviral factors included
in this study, MxA and TRIM22 maintained a statistically sig-
nificant association with viral load. The association between
MxA and HIV-1 viral load increased after adjusting for the
other antiviral factor expression variables, with every log in-
crease in MxA increasing the viral load by 0.85 log copies/ml
(P  0.0418). On the other hand, for every log increase in
TRIM22, the viral load decreased by 0.98 log copies/ml (P 
0.0307) (Table 2).
CD4 T-cell counts are an important correlate of disease
progression rate and outcome in HIV-1 infection. We there-
fore investigated whether IFN-, IFN-, MxA, huTRIM5,
and TRIM22 had any association with CD4 T-cell counts
during primary HIV-1 infection. A GEE model was fitted to
CD4 T-cell counts, adjusting for repeated measurements for
the same individual. In the univariate models, MxA, TRIM22,
IFN-, and IFN- all had significant a negative association
with CD4 T-cell counts; thus, as the expression increased with
1 log, CD4 T-cell counts decreased by 2.12, 1.79, 1.75, and
2.04 square root CD4 T cells/l for these factors, respectively.
However, in the multivariate model, only TRIM22 remained
statistically significant (P  0.0281), showing a positive associ-
ation with CD4 T-cell counts (Table 3).
TRIM22 expression is induced in HIV-negative PBMCs by
infection with HIV-1. We next sought to determine whether
infection of PBMCs isolated from HIV-negative donors could
induce TRIM22 expression in vitro. Infection of PBMCs in the
presence or absence of stimulating bispecific CD3.8 antibody
(11) resulted in the upregulation of the TRIM22 protein in
comparison to uninfected controls (Fig. 4A and B). The stim-
TABLE 2. Association between gene expression and viral loada
Geneb
Unadjusted model Adjusted model
Effect estimate (SE) P value Effect estimate (SE) P value
MxA 0.2887 (0.1436) 0.0444 0.8539 (0.4195) 0.0418
IFN- 0.2163 (0.1363) 0.1126 0.2512 (0.6476) 0.6981
IFN- 0.2216 (0.1345) 0.0995 0.1693 (0.4987) 0.7343
huTRIM5 0.0368 (0.1308) 0.7785 0.1539 (0.1439) 0.2851
TRIM22 0.2154 (0.1532) 0.1597 	0.9807 (0.4539) 0.0307
a A GEE model was fitted to viral load, adjusting for repeated measurements
for the same individual. Unadjusted models were fitted for each expression level
in order to determine the effect on viral load. An adjusted model was fitted,
including all expression variables in the model to determine whether they have
an effect while adjusting for other expression levels. Viral load and expression
level were log transformed to ensure normality. Boldface type indicates signifi-
cance.
b Versus GAPDH.
FIG. 3. Expression of type 1 IFN (MxA, IFN-, and IFN-) and TRIM22 mRNA in PBMCs at baseline (study enrollment) for nonserocon-
verters versus seroconverters. Participants included in this analysis were all enrolled as high-risk HIV-1-uninfected individuals and were longitu-
dinally monitored for at least 36 months each at the time of analysis. Data are depicted as the normalized ratio of IFN-, IFN-, MxA, and
TRIM22 versus GAPDH. The expression values were log transformed to ensure normality. The horizontal line represents the median. The
differences between groups were evaluated by using an unpaired Student’s t test. A P value of 0.05 was considered statistically significant.
TABLE 3. Association between gene expression and CD4 T-cell
counts after HIV infectiona
Geneb
Unadjusted model Adjusted model
Effect estimate (SE) P value Effect estimate (SE) P value
MxA 	2.1227 (0.8552) 0.0131 	4.1024 (2.3833) 0.0852
IFN- 	1.7526 (0.7378) 0.0175 	2.9797 (2.4699) 0.2277
IFN- 	2.0405 (0.6065) 0.0008 	0.8828 (2.3954) 0.7125
huTRIM5 	2.0405 (0.6065) 0.0008 	0.3175 (0.5683) 0.5764
TRIM22 	1.7936 (0.8945) 0.0450 6.0974 (2.7761) 0.0281
a A GEE model was fitted to CD4 T-cell counts, adjusting for repeated
measurements for the same individual. Unadjusted models were fitted for each
expression level in order to determine the effect on CD4 T-cell counts. An
adjusted model was fitted, including all expression variables in the model to
determine whether they have an effect while adjusting for other expression levels.
A square root transformation was applied to CD4 T-cell counts to ensure
normality. The expression level was log transformed. Boldface type indicates
significance.
b Versus GAPDH.
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ulation of PBMCs with CD3.8 antibody with no infection also
resulted in a slight increase in the TRIM22 expression level,
indicating that activation alone was enough to alter TRIM22
expression.
To validate the role of IFN- in TRIM22 induction, we
stimulated a number of cell lines used in HIV infection assays
(CEM, Jurkat, and THP-1) with increasing amounts of IFN-
and examined TRIM22 and huTRIM5 expression by reverse
transcription (RT)-PCR. IFN- significantly upregulated
TRIM22 and huTRIM5 expression in a dose-dependent
manner in all three cell lines tested (Fig. 4C and D).
Silencing of TRIM22 increases HIV infection and virus re-
lease in the presence of IFN-. To determine its functional role
in HIV infection, we tested the role of TRIM22 in HIV infec-
tion. JLTR-G reporter cells were stably transduced with empty
pLKO vector, control scrambled shRNA (control), or an
shRNA directed against the 3 untranslated region (3UTR) of
TRIM22 and then challenged with HIV-IIIB (a fully infectious
laboratory strain), with our without stimulation by IFN-. At
day 7, the percentage of HIV-infected cells (GFP-positive
staining) in the 3UTR cells treated with type 1 IFN exhibited
a significantly higher percentage of infected cells (51.2%) than
did vector-treated (22%) and control (24.5%) cells in the pres-
ence of IFN- (Fig. 5A). Furthermore, the percentage of in-
fected TRIM22-depleted cells was nearly equivalent regardless
of whether cells had been treated with IFN- or not, strongly
demonstrating a significant functional role for TRIM22 in the
anti-HIV IFN- response. Data for culture supernatants col-
lected on day 7 were consistent with these observations
when assessed for p24 levels by ELISA (Fig. 5B). The
knockdown of TRIM22 by the 3UTR shRNA in the pres-
ence of IFN- was validated by both RT-PCR and Western
blotting (Fig. 5C and D).
DISCUSSION
For species other than humans, it has been demonstrated
that restriction factors can completely block or partially restrict
retroviral infection (7, 8, 12, 24, 36). In contrast, little is known
about the in vivo regulation of restriction factors or their pos-
sible role in protecting or controlling retroviral infections in
humans. In this study, we used a well-characterized clinical
cohort of high-risk seronegative and acute or primary infection
samples to investigate the association of the expression of
select type 1 IFN isoforms, two well-characterized TRIM E3
ligases (TRIM5 and TRIM22), and the impact on HIV-1
susceptibility and viral control during primary HIV-1 infection.
Our earlier study revealed that lower huTRIM5 mRNA
expression levels were associated with increased susceptibility
to HIV-1 infection in a cohort of high-risk black African fe-
males (34). In addition, we found that in matched samples of
FIG. 4. Induction of TRIM22 expression by HIV and IFN-. Shown is a representative example of data for TRIM22 induction in PBMCs from
a healthy HIV-negative donor following infection with HIV-IIIB in the presence or absence of stimulating CD3.8 antibody. (A) Expression of
TRIM22 following HIV infection was assessed by Western blotting. Ran levels are shown as a loading control. (B) Relative fold induction of
TRIM22 by HIV averaged over three HIV-negative donors as determined by densitometric analysis (NIH Image). Values were normalized
to TRIM22 expression following CD3.8 stimulation and HIV infection in each donor. (C and D) Dose-dependent increases in TRIM22 (C) and
huTRIM5 (D) in various immune cell lines as determined by RT-PCR.
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HIV-1-negative individuals who later became HIV-1 positive,
huTRIM5 levels were not dysregulated following infection.
Here we sought to understand the relationship between
huTRIM5 and type 1 IFN in HIV-1-negative and -positive
donor PBMCs, in part because huTRIM5 is type 1 IFN in-
ducible (4, 31). Similarly, we also assessed the expression and
activity of the related TRIM22 protein, focusing on this protein
because, like TRIM5, it is IFN inducible and has been dem-
onstrated to have anti-HIV-1 activity (2, 4, 25). We found that
PBMCs from HIV-1-positive study subjects had higher levels
of IFN- and MxA, suggesting that these antiviral proteins are
actively upregulated following HIV-1 infection. This result is
consistent with findings from other groups (42, 44). We did not
see significant differences in IFN- expression between HIV-
1-negative and -positive PBMCs, suggesting that there may be
differences in the mobilization of the varied type 1 IFN iso-
forms (10, 23) following HIV-1 infection. However, overall, in
both HIV-1-negative and -positive PBMCs, we found a strong
positive correlation between the two type 1 IFN isoforms
tested and the IFN-inducible gene MxA, as previously de-
scribed (18). Surprisingly, huTRIM5 showed a significant in-
verse correlation with IFN- and had no association with
IFN- or MxA, even though huTRIM5 was shown previously
to be an IFN--inducible gene in vitro (31). These results could
reflect the limitations of our methodology here in analyzing
global expression in PBMCs rather than in specific constituent
cellular compartments or using frozen samples instead of fresh
samples. Alternatively, we can speculate that distinct type 1
IFN isoforms may differentially regulate huTRIM5 expres-
sion, or huTRIM5 expression in vivo may involve more-com-
plex pathways in addition to type 1 IFN. Further studies are
needed to comprehensively investigate how different type 1
IFN isoforms and other cellular proteins may function in the
regulation of huTRIM5 in different cellular environments
and varied cohorts.
Unlike huTRIM5, TRIM22 mRNA levels were higher in
HIV-1-positive participants than in HIV-1-negative ones. We
also found that TRIM22 correlated with IFN-, IFN-, and
MxA in both HIV-1-negative and -positive samples. These
results show an association between TRIM22 and type 1 IFN
expression in vivo, suggesting that TRIM22 is a type 1 IFN-
responsive gene in vivo, as was shown previously in in vitro
experiments (2, 3). Higher levels of IFN-, IFN-, MxA, and
TRIM22 were detected in seroconverters than in nonserocon-
verters at baseline, with differences reaching significance for
IFN- and TRIM22. These results suggest that there is im-
FIG. 5. TRIM22 silencing increases HIV infection and virus accumulation. (A) Jurkat reporter cells (LTR-G) transduced with the empty pLKO
vector, control shRNA, or an anti-TRIM22 shRNA targeting the 3UTR were infected with HIV-IIIB following a 1-day stimulation with IFN-.
Infection of JLTR-G cells (on day 7 postinfection) was assessed by GFP expression using flow cytometry. (B) TRIM22 silencing enhances
accumulation of HIV particles in culture supernatants as determined by p24 ELISA on day 7 postinfection. (C and D) JLTR-G cells transduced
with the indicated lentivirus were assessed for TRIM22 expression by RT-PCR and Western blotting. IFITM1 was used as a control (3a) for IFN
induction, while Ran was used as a loading control.
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mune activation or another dysfunction before these persons
become HIV-1 positive, and this may have contributed to the
increased susceptibility to infection for these study subjects. It
was previously demonstrated for a cohort of individuals at high
risk of HIV-1 acquisition that participants who remained se-
ronegative had lower levels of CD4 T-cell activation at base-
line (when both groups where HIV-1 negative) (16). Similarly,
levels of type 1 IFNs are elevated during immune activation,
which in turn has been associated with increased HIV-1/AIDS
pathology (19, 20). Further analysis of the dynamics of the
expression of these antiviral factors in matched pre- and
postinfection samples, especially from longitudinal cohorts of
low- and high-risk study subjects with frequent sampling, may
further help to better understand how intrinsic immunity is
mobilized in acute HIV-1 infection and its possible contribu-
tion to antiviral control, especially in the critical acute phase of
infection. It may also be useful to investigate the impact of
HIV-1 infection on the type 1 IFN pathway response genes in
mucosal tissues.
We also investigated the association of antiviral gene expres-
sion with viral load and CD4 T-cell counts, two commonly used
markers of disease progression. We found that MxA mRNA
levels showed a positive association with plasma viral load. For
every log increase in MxA, the viral load increased by 0.85 log
copies/ml. This is consistent with data from previous studies
that demonstrated that levels of type 1 IFN increase as the viral
load increases (18). Interestingly, we also observed that
TRIM22 has a negative association with plasma viral load and
a positive correlation with CD4 T-cell counts. We found that
for every log increase in TRIM22 mRNA levels, there is an
associated viral load decrease of 0.98 log copies/ml (P 
0.0307). TRIM22 also showed a positive association with
CD4 T-cell counts, as every log increase in TRIM22 expres-
sion was associated with a 6.09 square root increase in CD4
cells/l (P  0.0281).
The new findings of a paradoxical elevation of TRIM22
levels in HIV-positive versus HIV-negative PBMCs and the
favorable association of TRIM22 expression with markers of
disease outcome prompted us to investigate whether TRIM22
could be induced by HIV-1 infection of HIV-negative donor
PBMCs. Our experiments confirmed that TRIM22 was in-
duced by HIV (Fig. 5A and B) and provided an in vitro cor-
roboration of results demonstrating that HIV-1-positive sub-
jects have higher levels of TRIM22 than do HIV-negative
donors. This was similar to data from the work of Wang et al.
(43), who showed that pseudotyped HIV-1 infection could
induce APOBEC3G expression. Since PBMC populations are
composed of a number of immune cell types (T cells and
monocytes, etc.), we also demonstrated that IFN- exerts an
enhancing effect on TRIM22 expression in a dose-dependent
manner in CEM and Jurkat T-cell lines and the monocyte cell
line THP1 (Fig. 4C).
In addition, we found that the silencing of TRIM22 in a
T-cell line nearly completely abrogated the IFN-mediated re-
striction of HIV-1 (Fig. 5A). TRIM22 silencing also resulted in
an increased accumulation of HIV particles in culture super-
natants (Fig. 5B), suggesting a role for TRIM22 in late viral
replication activities, such as viral release or budding. Overall,
therefore, our results are in agreement with data from several
studies that have suggested that TRIM22 is induced by type 1
IFN and that TRIM22 can potently inhibit HIV replication
and release (2, 3, 37).
Together, these data are suggestive of both in vivo and in
vitro anti-HIV roles for TRIM22, although it is difficult to
prove a cause-effect relationship between TRIM22 expression
levels and viral load or CD4 T-cell count variables. Based on
our findings, we speculate that the targeted enhancement of
the expression of TRIM22 in HIV-1-infected individuals may
be beneficial in reducing the viral load and could be employed
as a novel antiviral strategy.
In conclusion, we have demonstrated with a cohort of HIV-
1-uninfected and -infected individuals in a high-prevalence set-
ting that HIV-1 infection is associated with an increased ex-
pression of the antiviral factor genes IFN- and MxA, key
components of the type 1 IFN pathway. However, we did not
find a correlation between IFN- or MxA and huTRIM5, a
previously described type 1 IFN-responsive host restriction
factor. Indeed, we found a significant negative correlation be-
tween IFN- and huTRIM5. In contrast, we found that
TRIM22 levels strongly correlated with IFN-, IFN-, and
MxA expression in both HIV-1-negative and -positive PBMCs
and were upregulated in HIV-1-positive study subjects. Re-
markably, TRIM22 was associated with lower plasma HIV
viral loads and higher CD4 T-cell counts in multivariate mod-
els adjusted for multiple antiviral factors analyzed, suggesting
that TRIM22 could have antiviral effects in vivo. We show in
vitro that TRIM22 is induced by type 1 IFN and HIV-1 infec-
tion. Furthermore, we demonstrate that TRIM22 plays a crit-
ical role in type 1 IFN-induced anti-HIV-1 activity in tissue
cultures. This is the first study to provide evidence suggesting
an in vivo antiviral activity of TRIM22. Further studies will be
needed to address what specific cell types in the PBMC milieu
express TRIM22 and the other members of the TRIM family,
to better define how the expression of these proteins is regu-
lated and to address whether these proteins can be harnessed
as antiviral therapies or prophylactics.
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